@MileHighCrow @shnitzerbittle @minnesota @DoctaPharm there sec filing indicates AMAG is reporting a defitcit of negative .5 or 1/2 million from other product revenue ie vyleesi (they itemize every other drug there selling) the 16 million was from collaborative revenue from another company see fine print. so vyleesi was losing them money which was expected in the beginning in the beginning since there giving it out for free, launch costs
  • 1
  • 19